Evaluate the Safety and Efficacy of TGR 1202 in Patients With Relapsed or Refractory Hematologic Malignancies

Inclusion Criteria:

- Refractory to or relapsed after at least 1 prior treatment regimen;

- Eastern Cooperative Oncology Group (ECOG) score of 0 to 2;

- At least 18 years of age.

Exclusion Criteria:

- Any major surgery, chemotherapy or immunotherapy within the last 21 days (limited
palliative radiation is allowed ≥ 2 weeks);

- Autologous hematologic stem cell transplant within 3 months of study entry or
Allogeneic hematologic stem cell transplant within 12 months;

- Known hepatitis B virus, hepatitis C virus or HIV infection;

- Previous therapy with GS-1101 (CAL-101), IPI-145 or any drug that specifically
inhibits the PI3K or mTOR pathway;